Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
about
New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphomaThe significance of FOXP1 in diffuse large B-cell lymphoma.Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOPFOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysisN-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo.
P2860
Q26765273-4FB05030-EACA-4B89-97A1-956873E5159AQ34047455-88D737E0-363D-41D5-9F8D-9F439B140BEFQ35145270-D6881597-A40A-47ED-AA93-8345DC72C78BQ35167200-DB09D23A-642E-45ED-A209-B61BAB5CCFACQ35755485-CE9CBFD4-A781-43A1-A2BB-F8C29C1F7893Q36302961-E7B48515-217E-41F1-910D-7F9E27A0491CQ36650112-91A59351-CCA6-406F-B68E-8B1E6C2280F2Q37125561-C28D6662-72F8-4EC9-AC47-A81C17E8D2D6Q37216467-81D2C396-6E79-4FEC-B7F0-9FDBEC9F2646Q37458938-EBF0CE6A-A694-4312-8B2B-F766D6C582AAQ37619689-9C5B5001-D3BF-4260-9408-4C1D7EF57E2FQ37725413-3CF359CC-0DC1-49F7-BAAD-4D964F023F72Q38840351-F6B57983-1576-40AB-8F5D-8DD03F32619FQ38935940-0AE9B47F-5FCF-4E3B-9542-D5B711862FB8Q44315979-B6116710-58DE-40F9-A5EA-9AE1CB6B94F9
P2860
Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Reciprocal expression of the e ...... arge B-cell lymphoma patients.
@en
Reciprocal expression of the e ...... arge B-cell lymphoma patients.
@nl
type
label
Reciprocal expression of the e ...... arge B-cell lymphoma patients.
@en
Reciprocal expression of the e ...... arge B-cell lymphoma patients.
@nl
prefLabel
Reciprocal expression of the e ...... arge B-cell lymphoma patients.
@en
Reciprocal expression of the e ...... arge B-cell lymphoma patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Reciprocal expression of the e ...... large B-cell lymphoma patients
@en
P2093
D M Gascoyne
L M Pedersen
R D Gascoyne
P2860
P2888
P304
P356
10.1038/LEU.2013.224
P50
P577
2013-07-25T00:00:00Z
P5875
P6179
1025093505